SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund ($VCX) is seeing intense volatility and speculative interest following its recent market debut, with the community actively debating whether it is a legitimate vehicle for private equity exposure or a highly overvalued pump-and-dump scheme. Investors are fixated on the fund's heavy concentration in high-profile pre-IPO tech firms like Anthropic and SpaceX, while many remain frustrated by a six-month lock-up period that limits liquidity for early participants.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is facing significant downward pressure and intense community debate surrounding regulatory risks, Medicare reimbursement uncertainty, and potential balance sheet strain. While some investors see a long-term value opportunity at current levels, others are expressing concern over the company's technical weakness and its ability to navigate a challenging macroeconomic and political landscape.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is attracting investor interest following recent insider buying from CEO Seth Lederman and positive developments in the commercial launch of their fibromyalgia treatment, TONMYA. While shareholders remain focused on the potential for future institutional growth and strategic partnerships, community discussions are currently centered on navigating ongoing volatility, monitoring weekly prescription trends, and evaluating the company's long-term cash runway.

The Graph is an indexing protocol and global API for organizing blockchain data and making it easily accessible with GraphQL. Developers can use Graph Explorer to search, find, and publish all the public data they need to build decentralized applications. The Graph Network makes it possible to build serverless dApps that run entirely on public infrastructure.  GRT is the native token of the network that’s used to coordinate work. GRT is an ERC20 token. Node operators, called Indexers, stake and earn GRT for processing queries. Anyone can delegate GRT to Indexers to secure the network and earn rewards. Curators organize data on The Graph by signaling GRT on useful APIs, called subgraphs. Indexers, Delegators, and Curators work together to organize the data for the crypto economy and maintain a useful global API for DeFi and Web3.

The Graph

The Graph is capturing significant community attention as investors debate its role as critical web3 infrastructure versus concerns over token supply dilution, while recent protocol upgrades like the integration of Anthropic's Model Context Protocol continue to drive technical interest. While some traders view the current price as an undervalued accumulation opportunity for the long term, others remain skeptical, focusing on historical price volatility and questioning whether the project can reclaim its prior highs.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

The SPERMWHALE meme coin is generating significant buzz as traders debate whether it could replicate the explosive momentum seen in similar speculative crypto assets. While some investors focus on signs of accumulation and relative price stability, others remain skeptical, warning of the risks inherent in such volatile market activity.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending following the announcement of a full notice to proceed on a $2.4 billion contract to provide natural gas-fired power generation for AI data centers, a development the community views as a major valuation catalyst. Investors are actively discussing the company's long-term growth potential in the AI infrastructure space and its strategic relationship with Applied Digital, while debating whether the stock's recent volatility is due to institutional accumulation or ongoing short-seller manipulation.

The Estée Lauder Companies, Inc. engages in the manufacture of skin care, makeup, fragrance and hair care products. It sells products under Estée Lauder, Clinique, Origins, MAC, Bobbi Brown, La Mer, Jo Malone London, Aveda and Too Faced. The company was founded by Estee Lauder and Joseph Lauder in 1946 and is headquartered in New York, NY.

Estee Lauder Cos., Inc. - Ordinary Shares - Class A

Estee Lauder Cos. Inc

Estee Lauder is at the center of investor focus following reports that it is in merger discussions with Spanish beauty group Puig. While the market is reacting to potential dilution risks and broader concerns over debt, the community is actively debating the deal's strategic viability versus its potential downside, with some seeing a long-term turnaround opportunity.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is currently trending due to a wave of positive institutional momentum, highlighted by Cathie Woods ARK Invest aggressively increasing its stake and a series of strategic international expansion wins, including live driverless operations in the Middle East. The community is actively discussing the stock's significant valuation discount relative to peers like Waymo and Pony.ai, with many investors debating whether the companys pivot toward scalable, diversified autonomous product lines will finally force a market rerating.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending due to persistent M&A speculation, with investors closely watching reports of a potential multibillion-dollar buyout by major pharmaceutical players like Eli Lilly and AstraZeneca. The community is actively discussing the stock's significant valuation premium, the impact of recent clinical data and analyst target increases, and the implications of potential government regulatory scrutiny in France.

Merlin, Inc. is an aerospace and defense technology company focused on developing autonomous flight solutions. The company is building an operating system of record for autonomous aviation, with its Merlin Pilot system enabling a wide range of aircraft and mission profiles. Its technology has been validated through hundreds of autonomous flights conducted at test facilities worldwide. The company is headquartered in Boston, MA.

Merlin Inc.

Marlin Business Services Corp.

The community is currently navigating significant confusion regarding the ticker $MRLN, with many investors debating whether it refers to Marlin Business Services or the recently listed AI-aviation firm Merlin, Inc. Traders are closely monitoring the stock for potential high-volatility momentum, especially as participants compare its market behavior to other low-float runners.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Brokerages

Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has earned an average rating of "Hold" from the eight ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and three have...

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 14.1% in February

Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) was the recipient of a large drop in short interest in the month of February. As of February 27th, there was short interest totaling 9,563,527...

Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference

Fate Therapeutics (NASDAQ:FATE) CEO Bob Valamehr outlined the company's clinical and manufacturing strategy for FT819, an off-the-shelf allogeneic CAR T-cell therapy, during a conference fireside...

Fate Therapeutics (NASDAQ:FATE) Posts Earnings Results, Meets Expectations

Fate Therapeutics (NASDAQ:FATE - Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, meeting analysts...

Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of +1.21% and -8.73%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Summary: Fate Therapeutics Q4

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts

Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has been given a consensus recommendation of "Hold" by the nine research firms that are presently covering the stock, MarketBeat Ratings...

Fate Therapeutics (FATE) to Release Earnings on Wednesday

Fate Therapeutics (NASDAQ:FATE) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 4. (View Earnings Report at...

Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving Average - What's Next?

Fate Therapeutics (NASDAQ:FATE) Stock Passes Above 50 Day Moving Average - Time to Sell...

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have received a consensus recommendation of "Hold" from the nine analysts that are covering the firm, Marketbeat.com reports. One...

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

FATE
Fate Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest FATE News

FATEFate Therapeutics Inc